Bicara Therapeutics Inc
bicara.comWhat Do They Do?
Develops antibody treatments designed to target tumors and block a tumor signal for patients with solid tumors, including head and neck cancer.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid…View ↗
We believe ficerafusp alfa has the potential to provide meaningful clinical benefit in solid tumors that are challenged by inadequate tumor…View ↗
Ficerafusp alfa is a bifunctional antibody that combines the well-established biologies of two targets—the anti-EGFR antibody, cetuximab…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$55.4MView ↗
- ▲ +102% (Loss)
- vs −$27.4M in Q2 FY2025
Who Do They Compete With?
Competes with Akeso, AstraZeneca, AVEO Pharmaceuticals, BioAtla, BioNTech, Corbus Pharmaceuticals Holdings, GSK, InhibRx Biosciences, Johnson & Johnson, Merus, PDS Biotechnology, Pyxis Oncology, and Rakuten Medical
10-K for FY2025, filed Mar 30, 2026We expect to compete with currently commercially available therapies for the treatment of HNSCC, including pembrolizumab (marketed as…View ↗
Loading...
